The anti-cancer activity of TA is associated with the degradation of the specificity protein 1 (Sp1) transcription factor and the inhibition of expression of its downstream targets such as cMet, VEGF, and Survivin [15, 16, 18]. Here, BIRC5 is linked to cancer.